Evidence summaries: new medicines are provided to help commissioners, budget holders and groups such as Area Prescribing Committees to make informed decisions and aid local planning on the introduction of key new medicines.
They are quality-assured summaries of the best available evidence for selected new medicines, or existing medicines with new indications or a new formulation, that are considered to be of significance to the NHS. The topics selected are medicines that have recently gone into the UK market, or medicines that may be marketed in the UK in the next 6–12 months.
The strengths and weaknesses of the relevant evidence are critically reviewed, but the Evidence summaries: new medicines are not formal NICE guidance.
Further information about Evidence summaries: new medicines can be found on the NICE website.
Next > >>
Next > >>
